CRE Homepage About The CRE Advisory Board Newsletter Search Links Representation Comments/Ideas
Data Access
Data Quality
Regulation by Litigation
Regulation by Appropriation
Special Projects
CRE Watch List
OMB Papers
Abstracts and Reviews
Regulatory Review
Voluntary Standards Program
CRE Report Card
Public Docket Preparation
Consumer Response Service
Site Search

Enter keyword(s) to search

®: CRE Regulatory Action of the Week

Information Quality Guidelines: EPA Ban on Third Party Clinical Human Test Data Violates Data Quality Act
CRE has informed EPA that the agency's ban on third party clinical human test data, pending National Academy of Sciences (NAS) review, violates the Data Quality Act. In its letter to EPA, the Center points out that these data are among the best available information regarding any substance's risk to human health, and the Act requires the agency to consider and use the best available data on health risks. Therefore, EPA's categorical refusal to consider these data is a clear violation of the Act and OMB's implementing Data Quality guidelines. CRE urges EPA to change its position now. CRE is including this letter as part of its comments on EPA's proposed Data Quality guidelines.

  • Click to read CRE's letter to EPA
  • Click to read Exhibits to the CRE letter
  • CRE Regulatory Services
  • Click to submit a comment

    CRE Exhibits

  • EPA Headquarters Press Release - Agency Requests National Academy of Sciences Input on Consideration of Certain Human Toxicity Studies; Announces Interim Policy - December 14, 2001

  • EPA Letter to the National Academy of Sciences - December 14, 2001

  • The Value of Human Testing of Pesticides

  • Using Human Data to Protect the Public's Health

  • CRE Letter to EPA - August 22, 2000

  • Examples of EPA Use of Clinical Human Test Data

  • Air Pollution Inhalation Chambers Dedicated for Human Health Research